• Doctor education continues to be core to Khiron mission
  • Partnership allows Khiron to include its medical education program with Tecnologico de Monterrey world-renowned continuing education platform for doctors, giving it prominent exposure to the Latin America medical community
  • Co-developed, online educational content will focus on medical cannabis knowledge, application and potential therapeutic benefits of cannabinoid-based medicines to better meet patient needs
  • Tecnologico de Monterrey, a top-3 Latin American university and the leading university in Mexico (Source: QS University Rankings)
  • Khiron’s Phase 1, best in class cloud-based cannabis education and certification platform will be launched in Q2 2020 and feature interactive courses customized for specific medical cannabis conditions

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN), (OTCQB:KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced the Company has entered into an agreement  with Tecnologico de Monterrey in Mexico bringing science-based online medical cannabis education to an initial group of up to 1,500 healthcare practitioners. With costs covered by Khiron, the program launches the Company’s Latin America medical cannabis education strategy, positioning Khiron as a leader in increasing the understanding and application of cannabinoid therapies in the region.

“In the new reality of Covid-19, the development of online continuing medical education programs with highly scientific content is critical to fulfill current gaps and support needed in medical cannabis academic training among healthcare practitioners. Our doctor education strategy, and relationship with Tecnologico de Monterrey in Mexico, encourages our person-centred care, and contributes to our commitment to medical cannabis education and responsible prescription of cannabinoid therapy,” comments Rodrigo Duran, Khiron VP Pharma.

Tecnologico de Monterrey medical cannabis program begins with online based courses in Q2 2020, introducing healthcare providers across Latin America to specific regulatory frameworks, clinical evidence and research, safety considerations, clinical cases and practical recommendations to best meet current patient needs. A second phase will launch in Q3 2020.

“As the leading university in Mexico we have a responsibility to bring the highest level of education to our physician population including different specialities of physicians. In the emerging field of medical cannabis, the partnership with Khiron Life Sciences means we can do this in an informed, science-based environment that will raise knowledge among Latin American healthcare professionals and prepare them to bring greater treatment options to patients,” comments Gabriela Villarreal Levy MD, MPH, Associate Dean of Continuing Medical Education at Tecnologico de Monterrey.

“This partnership continues Khirons innovation model in reaching doctors and patients virtually, including our recently announced teleconsultation service which allows patients, including those in our ILANS and Zerenia clinics to access clinic services and doctors trained to prescribe medical cannabis,” comments Alvaro Torres, Khiron CEO and director.

Khiron will host an investor webcast with Alvaro Torres, CEO and Chris Naprawa, President, to discuss its medical cannabis education strategy and further Company activity.

DATE: Monday, April 6, 2020
TIME: 11:00am ET/8:00am PST
FORMAT: Live 20 minutes presentation & 10-minute Q&A session
LINK: https://event.on24.com/wcc/r/2256382/47BC8B35460B3AC1B73FBDB2F7BE4496

About the Tecnologico de Monterrey
Founded in 1943, the Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM) (in English: Monterrey Institute of Technology and Higher Education), also known as Tecnológico de Monterrey, is a secular and co-ed multi-campus private university based in Monterrey, Mexico.  Tecnologico de Monterrey has since grown to include 36 campuses throughout the country, quickly becoming one of the best universities in Latin America.

Tecnologico de Monterrey was the first university to be connected to the internet in Latin America and the Spanish speaking world having the top-ranked business school in the region according to the Economist. The medical school offers the only MD-PhD program available in Mexico, in partnership with the Houston Methodist Hospital.

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Latin America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The Company delivers best in class regulatory compliance, has the first approved line of CBD cosmetic products on shelf in Colombia, and is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis in the country.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Visit Khiron online at www.khiron.ca and on Instagram @khironlife

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN, OTC:KHRNF) for an Investor Presentation.


Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less